$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of ESSA Pharma Inc. (NASDAQ: EPIX)

Core Viewpoint - The article discusses the investigation by Monteverde & Associates PC into the sale of ESSA Pharma Inc. to Xeno Acquisition Corp., highlighting the financial implications for ESSA shareholders and questioning the fairness of the deal [1]. Summary by Relevant Sections Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1]. Transaction Details - ESSA shareholders will receive a cash payment per share based on ESSA's cash balance at closing, minus transaction costs, liabilities, and a $4 million transaction fee to Xeno [1]. - Shareholders are also entitled to one non-transferable contingent value right per share, which includes potential future payments of up to $150,000, less remaining liabilities and expenses, and up to $2.8 million, less legal and other expenses incurred after closing [1]. Legal Context - The firm emphasizes the importance of legal representation for shareholders and offers free consultations regarding concerns related to the transaction [2][3].